Myriad Genetics, Inc.

MYGN Healthcare Diagnostics & Research

Myriad Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $824.5 million, down 1.56% from fiscal 2024. In the quarter to June 2026, revenue fell 10.5%, EPS grew 87.1%, free cash flow grew 43.9% and total debt rose 103.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.98 0.37 −8.51%
Market cap
$416.1M
P/E
0.0×
Fwd P/E
−6.0×
Dividend yield
—
F-score
5/9
Altman Z
−1.52
Beneish M
−5.42
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '19 Jun '20 Dec '20 Jun '21 Dec '21 Jun '22 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
136.90 217.80 150.70 340.00 338.80 117.00 114.90 140.90 102.40 149.60
Receivables
138.60 71.00 89.50 91.00 91.30 102.00 101.60 114.30 121.20 115.30
Inventory
31.40 29.10 27.10 15.00 15.30 20.00 20.10 22.00 27.50 30.60
Total current assets
348.60 331.70 389.40 485.00 484.80 275.00 274.60 313.60 298.00 332.60
Property, Plant, Equpment (Net)
57.30 37.00 40.70 125.00 43.50 187.00 83.40 119.00 117.40 114.00
Long-Term Investments
54.90 37.00 21.00 59.00 59.00 62.00 54.80 — — —
Goodwill and Intangible Assets (Total)
1,101.90 932.90 905.70 643.00 643.30 667.00 666.50 636.90 548.70 205.00
Long-term assets (Other)
— 66.00 2.30 8.00 8.30 8.00 15.50 15.40 8.50 5.60
Total non-current assets
1,214.10 1,072.90 1,029.40 — 835.90 — 924.10 832.90 729.60 374.00
Total Assets
1,562.70 1,404.60 1,418.80 1,414.00 1,320.70 1,317.00 1,198.70 1,146.50 1,027.60 706.60
Accounts Payable
33.30 21.70 20.50 30.00 29.60 29.00 28.80 25.80 32.30 30.00
Accrued Expenses
78.90 75.90 79.10 — 161.70 — 94.30 113.90 119.00 96.90
Current Revenue (Deferred)
2.20 32.80 32.70 — 5.20 — — — — —
Other current liabilities
3.40 3.10 — — — — — — — —
Total current liabilities
117.80 147.00 145.90 204.00 204.30 137.00 137.20 155.90 164.10 133.80
Long Term Debt (Total)
233.50 224.40 224.80 79.00 — 131.00 — 38.50 39.60 119.90
Long Term Tax Liability (Deferred)
82.60 26.60 71.30 36.00 35.80 — — — — —
Non-current Liabilities (Other)
39.90 31.50 45.20 34.00 33.50 42.00 44.80 71.50 34.90 1.90
Total non-current liabilities
356.00 339.40 391.90 — 148.60 — 175.70 207.40 162.40 204.80
Total liabilities
473.80 486.40 537.80 446.00 352.90 431.00 312.90 363.30 326.50 338.60
Additional Paid In Capital
1,068.00 1,096.60 1,109.50 — 1,226.30 — 1,260.10 1,415.50 1,457.80 1,489.00
Common Stock (Net)
0.70 0.70 0.80 1.00 0.80 1.00 0.80 0.90 0.90 0.90
Retained Earnings
25.60 (173.90) (227.00) (254.00) (254.20) (366.00) (366.20) (629.50) (756.80) (1,122.70)
Common Equity (Total)
1,088.90 918.20 881.00 968.00 967.80 886.00 885.80 783.20 701.10 368.00
Shareholders Equity (Total)
1,088.90 918.20 881.00 968.00 967.80 886.00 885.80 783.20 701.10 368.00
Shareholders Equity and Liabilities (Total)
1,562.70 1,404.60 1,418.80 — 1,320.70 — 1,198.70 1,146.50 1,027.60 706.60
Shares (Common)
73.50 74.70 75.40 — 80.00 — 81.20 89.90 91.30 93.50
Shareholders Equity (Tangible)
(13.00) (14.70) (24.70) — 324.50 — 219.30 146.30 152.40 163.00
Net Debt
96.60 6.60 74.10 (261.00) (338.80) 14.00 (114.90) (102.40) (62.80) (29.70)
Total Debt
233.50 224.40 224.80 79.00 — 131.00 — 38.50 39.60 119.90

Fold the line items

In millions of $ except per-share values · columns are period end dates